Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

pembrolizumab 2anlotinib 2Pemetrexed 2Paclitaxel 2Bevacizumab 2relacorilant 1olaparib 1niraparib 1nilotinib 1lenvatinib 1Therapeutic Touch 1Radiotherapy 1Ocoxin 1Nivolumab 1Laparoscopy 1Ipilimumab 1Filgrastim 1Electrocardiography 1Darbepoetin alfa 1Carboplatin 1CP protocol 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Genital Neoplasms, Female × Ipilimumab × Clear all
NCT04969887 2026-02-27

MOST-CIRCUIT

Olivia Newton-John Cancer Research Institute

Phase 2 Active not recruiting
240 enrolled
EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡